Co-Authors
This is a "connection" page, showing publications co-authored by Marek Jutel and Oscar Palomares.
Connection Strength
0.577
-
Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)H. Allergol Select. 2020; 4:53-68.
Score: 0.225
-
Management of anaphylaxis due to COVID-19 vaccines in the elderly. Allergy. 2021 10; 76(10):2952-2964.
Score: 0.061
-
COVID-19 pandemic and allergen immunotherapy-an EAACI survey. Allergy. 2021 11; 76(11):3504-3516.
Score: 0.060
-
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy. 2021 06; 76(6):1629-1639.
Score: 0.059
-
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper. Allergy. 2021 03; 76(3):648-676.
Score: 0.058
-
Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. Allergy. 2020 11; 75(11):2764-2774.
Score: 0.057
-
Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2020 10; 75(10):2445-2476.
Score: 0.057